Clinical Trials
4 trialsNCT03491683 2026-05-04
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT03502785 2025-07-10
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Inovio Pharmaceuticals
Phase 1/2 Completed
NCT02172911 2021-02-21
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
Inovio Pharmaceuticals
Phase 1/2 Completed
NCT02163057 2021-01-22
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 1/2 Completed